Operator of a biotechnology platform intended to develop small molecule compound to lower cholesterol. The company's platform focuses on offering an orally-bioavailable small molecule PCSK9 inhibitor by strategically focusing on small molecule inhibitors, enabling clients to dramatically disrupt the health economics of PCSK9-based therapies.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Early Stage VC | 00.00 | Completed | Startup | |||
2. Early Stage VC (Series A) | 01-Apr-2017 | 00.00 | 00.00 | 000.00 | Completed | Startup |
1. Accelerator/Incubator | 01-Jan-2017 | $2M | $2M | Completed | Startup |
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A-2 | 000,000 | 00.000000 | 00 | 000.00 | 000.00 | 00 | 000.00 | 000 |
Series A-1 | 000,000 | 00.000000 | 00 | 000.00 | 000.00 | 00 | 000.00 | 00.000 |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Brian Hubbard Ph.D | Co-Founder & Chief Executive Officer | ||
Doug Daniels | Co-Founder | ||
Virendar Kaushik | Co-Founder |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
JMCR Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
Viva BioInnovator | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | |
Daoyuan Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
Sprout Bioventures | Venture Capital | Minority | 000 0000 | 000000 0 |